Blue Cross Attacks Janssen Prostate Cancer Drug 'Monopoly'
Blue Cross Blue Shield accused Janssen Biotech of misusing patent infringement suits to keep generic versions of prostate cancer drug Zytiga at bay, telling a Virginia federal judge the drug giant...To view the full article, register now.
Already a subscriber? Click here to view full article